Therapeutic effect of tempo in Mozart's "Sonata for two pianos" (K. 448) in patients with epilepsy: An electroencephalographic study.


Journal

Epilepsy & behavior : E&B
ISSN: 1525-5069
Titre abrégé: Epilepsy Behav
Pays: United States
ID NLM: 100892858

Informations de publication

Date de publication:
08 2023
Historique:
received: 02 02 2023
revised: 08 06 2023
accepted: 09 06 2023
medline: 7 8 2023
pubmed: 26 6 2023
entrez: 25 6 2023
Statut: ppublish

Résumé

Mozart's "Sonata for two pianos" (Köchel listing 448) has proven effective as music therapy for patients with epilepsy, but little is understood about the mechanism of which feature in it impacted therapeutic effect. This study explored whether tempo in that piece is important for its therapeutic effect. We measured the effects of tempo in Mozart's sonata on clinical and electroencephalographic parameters of 147 patients with epilepsy who listened to the music at slow, original, or accelerated speed. As a control, patients listened to Haydn's Symphony no. 94 at original speed. Listening to Mozart's piece at original speed significantly reduced the number of interictal epileptic discharges. It decreased beta power in the frontal, parietal, and occipital regions, suggesting increased auditory attention and reduced visual attention. It also decreased functional connectivity among frontal, parietal, temporal, and occipital brain regions, also suggesting increased auditory attention and reduced visual attention. No such effects were observed after patients listened to the slow or fast version of Mozart's piece, or to Haydn's symphony at normal speed. These results suggest that Mozart's "Sonata for two pianos" may exert therapeutic effects by regulating attention when played at its original tempo, but not slower or faster. These findings may help guide the design and optimization of music therapy against epilepsy.

Sections du résumé

BACKGROUND
Mozart's "Sonata for two pianos" (Köchel listing 448) has proven effective as music therapy for patients with epilepsy, but little is understood about the mechanism of which feature in it impacted therapeutic effect. This study explored whether tempo in that piece is important for its therapeutic effect.
METHODS
We measured the effects of tempo in Mozart's sonata on clinical and electroencephalographic parameters of 147 patients with epilepsy who listened to the music at slow, original, or accelerated speed. As a control, patients listened to Haydn's Symphony no. 94 at original speed.
RESULTS
Listening to Mozart's piece at original speed significantly reduced the number of interictal epileptic discharges. It decreased beta power in the frontal, parietal, and occipital regions, suggesting increased auditory attention and reduced visual attention. It also decreased functional connectivity among frontal, parietal, temporal, and occipital brain regions, also suggesting increased auditory attention and reduced visual attention. No such effects were observed after patients listened to the slow or fast version of Mozart's piece, or to Haydn's symphony at normal speed.
CONCLUSIONS
These results suggest that Mozart's "Sonata for two pianos" may exert therapeutic effects by regulating attention when played at its original tempo, but not slower or faster. These findings may help guide the design and optimization of music therapy against epilepsy.

Identifiants

pubmed: 37356223
pii: S1525-5050(23)00242-1
doi: 10.1016/j.yebeh.2023.109323
pii:
doi:

Substances chimiques

zaleplon S62U433RMH

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

109323

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Rui Ding (R)

The Clinical Hospital of Chengdu Brain Science Institute, MOE Key Lab for Neuroinformation, University of Electronic Science and Technology of China, Chengdu 611731, Sichuan, China; Center for Information in Medicine, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu 611731, Sichuan, China; Montreal Neurological Institute, McGill University, Montreal, QC, Canada, H3A 2B4. Electronic address: rui.ding@std.uestc.edu.cn.

Huajuan Tang (H)

Department of Neurology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China; Department of Neurology, 363 Hospital, Chengdu 610041, Sichuan, China. Electronic address: t_tanghj@163.com.

Ying Liu (Y)

The Clinical Hospital of Chengdu Brain Science Institute, MOE Key Lab for Neuroinformation, University of Electronic Science and Technology of China, Chengdu 611731, Sichuan, China; Center for Information in Medicine, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu 611731, Sichuan, China. Electronic address: 852397654@qq.com.

Yitian Yin (Y)

The Clinical Hospital of Chengdu Brain Science Institute, MOE Key Lab for Neuroinformation, University of Electronic Science and Technology of China, Chengdu 611731, Sichuan, China; Center for Information in Medicine, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu 611731, Sichuan, China. Electronic address: 2629028799@qq.com.

Bo Yan (B)

Department of Neurology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China. Electronic address: yanbo96@163.com.

Yingqi Jiang (Y)

Department of Neurology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China. Electronic address: rzx721109@foxmail.com.

Paule-J Toussaint (PJ)

Montreal Neurological Institute, McGill University, Montreal, QC, Canada, H3A 2B4. Electronic address: paule.toussaint@mcgill.ca.

Yang Xia (Y)

Center for Information in Medicine, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu 611731, Sichuan, China. Electronic address: xiayang@uestc.edu.cn.

Alan C Evans (AC)

Montreal Neurological Institute, McGill University, Montreal, QC, Canada, H3A 2B4. Electronic address: alan.evans@mcgill.ca.

Dong Zhou (D)

Department of Neurology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China. Electronic address: zhoudong66@yahoo.de.

Xiaoting Hao (X)

Department of Neurology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China. Electronic address: sherryhao@wchscu.cn.

Jing Lu (J)

The Clinical Hospital of Chengdu Brain Science Institute, MOE Key Lab for Neuroinformation, University of Electronic Science and Technology of China, Chengdu 611731, Sichuan, China; Center for Information in Medicine, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu 611731, Sichuan, China. Electronic address: lujing@uestc.edu.cn.

Dezhong Yao (D)

The Clinical Hospital of Chengdu Brain Science Institute, MOE Key Lab for Neuroinformation, University of Electronic Science and Technology of China, Chengdu 611731, Sichuan, China; Center for Information in Medicine, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu 611731, Sichuan, China. Electronic address: dyao@uestc.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH